Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta-analysis

Lee, Young Ho; Song, Gwan Gyu

doi:10.1111/ced.13381

Cited by 49 publications

(45 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are evidences that psoriatic patients had significantly lower serum 25(OH)D concentrations than the healthy controls [16, 29, 30] and the prevalence of vitamin D deficiency (<20 ng/ml) was significantly higher in psoriatic patients than in the controls [14]. Our study showed a higher proportion of patients with vitamin D deficiency at baseline which is almost fivefold higher than the Thai population prevalence of 5.7% [31].…”

Section: Discussionmentioning

confidence: 43%

“…Psoriasis is a multisystem inflammatory disorder with multiple associated comorbidities, such as psoriatic arthritis, obesity, metabolic syndrome, cardiovascular, and cerebrovascular diseases [2, 6, 11–13]. Several studies showed that circulating 25 hydroxyvitamin D (25(OH)D) levels were significantly lower among patients with psoriasis than healthy controls [14–16]. Abnormal vitamin D metabolism may play a role in the pathogenesis of psoriasis [17, 18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

Disphanurat

Viarasilpa

Chakkavittumrong

et al. 2019

Dermatology Research and Practice

View full text Add to dashboard Cite

Background. There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and the results are inconclusive. Objective. To investigate the clinical effect of oral vitamin D supplementation on psoriasis. Methods. Patients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks for 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months after treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events were monitored. The chi-square test, Fisher’s exact test, Student’s t-test, and Spearman’s correlation analysis were used in statistical analysis. Results. Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group (n=22). At enrollment, the mean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency. At 3 months, the oral vitamin D2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33, p-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly higher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum 25(OH)D concentrations were significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall. Conclusion. Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly improved the treatment outcome without increasing adverse events. Trial Registration. This trial is registered with Thai Clinical Trials Registry TCTR20180613001.

show abstract

Section: Discussionmentioning

confidence: 43%

Section: Introductionmentioning

confidence: 99%

The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

Disphanurat

Viarasilpa

Chakkavittumrong

et al. 2019

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…In fact, low 25(OH)D levels can either represent the cause or consequence of psoriasis, resulting from lack of sun exposure, from frequent use of drugs that interfere with 25(OH)D metabolism (such as gluco-corticoids and immunosuppressive agents), or from low 25(OH)D intake. [ 16 , 17 ]…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, those affected by long-time psoriasis, and not undergoing phototherapy, could possibly be more prone to vitamin D reduced serum levels. [ 17 ]…”

Section: Discussionmentioning

confidence: 99%

Association between psoriasis and vitamin D

Filoni¹,

Vestita²,

Congedo

et al. 2018

Medicine

View full text Add to dashboard Cite

Recent literature has focused on the association of psoriasis with lower than normal or highly deficient vitamin D blood levels.To investigate the controversial association between psoriasis and vitamin D levels.From 2012 to 2014, 561 subjects were assessed, of which 170 had psoriasis, 51 had an autoimmune bullous, and 340 were healthy patients. Anagraphical data, 25(OH)D blood levels, and seasons of vitamin D levels assessments were recorded for each group.Vitamin D levels were significantly different among the 3 groups (K = 151.284; P = .0001). Psoriatic patients had significantly lower serum levels of 25(OH)D (21.8 ng/mL) than healthy controls (34.3 ng/mL) (chi-square = 11.5; P = .0007). Patients with bullous diseases showed the lowest vitamin D mean values (18.2 ng/mL). The linear multiple regression model showed 25(OH)D levels to be influenced by age, season of blood vitamin D levels assessment, and psoriasis duration.These results confirm the reduced vitamin D levels in psoriatic patients when compared to healthy controls, and provide new evidence regarding the association of vitamin D levels and psoriasis duration. The limits of our study include its observational nature and the small number of patients undergoing biological immunosuppressive therapies.

show abstract

“…Studies by Orgaz‐Molina et al and Hassab‐El‐Naby et al reported that there was no relationship between 25(OH)D 3 levels and Psoriasis Area Severity Index (PASI) 7,8 . However, studies by Bergler‐Czop et al , Tajjour et al , Lee et al , and Ingram et al reported a significant negative correlation between serum levels of 25(OH)D 3 with PASI score 9–12 …”

Section: Introductionmentioning

confidence: 99%

Pilot study: immunohistochemistry expressions of vitamin D receptor associated with severity of disease in psoriasis patients

2020

View full text Add to dashboard Cite

Background Psoriasis is a chronic inflammatory skin disorder characterized by keratinocyte hyperproliferation, differentiation abnormalities, and resistance to apoptosis. There are several factors that can affect psoriasis and vitamin D is one of the recently arisen. The role of vitamin D is mediated by vitamin D receptors (VDR) in target cells. VDR is a nuclear hormone that is involved in the antiproliferation and pro‐differentiation pathways in keratinocytes. However, until now vitamin D/VDR signaling in psoriasis has not been fully understood. Methods A cross‐sectional study that involved 28 skin specimens from psoriasis patients to assess the immunohistochemistry expressions of VDR as well as their association with severity and duration of psoriasis. Statistical analyses were performed using Spearman's correlation coefficients, with P <0.05 was considered statistically significant. Results In total, 28 specimens from psoriasis patients consisting of 60.7% women and 39.3% men, with mean age 41.28 ± 14.97 years, predominantly age group 46–55 years (25%), mean duration of disease 6.64 ± 4.26 years, and mean Psoriasis Area and Severity Index (PASI) score 19.23 ± 11.30. The immunohistochemistry expressions of VDR were predominantly strong (57.1%) and located in the basal layer (53.6%). There were a significant negative correlation between the expressions of VDR and PASI score (P <0.001, r = −0.719) and between the expressions of VDR and duration of disease in psoriasis (P = 0.020, r = −0.438). Conclusion VDR expressions and severity of psoriasis showed a strong significant negative correlation and also a moderate significant negative correlation between VDR expressions and duration of disease.

show abstract

Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta-analysis

Abstract: This meta-analysis demonstrated that circulating 25(OH)D levels are lower in patients with psoriasis, and that a small but statistically significant negative correlation exists between 25(OH)D levels and psoriasis severity.

Cited by 49 publications

References 21 publications

The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

Association between psoriasis and vitamin D

Pilot study: immunohistochemistry expressions of vitamin D receptor associated with severity of disease in psoriasis patients

Contact Info

Product

Resources

About